Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data.

Muro K, Salinardi T, Singh AR, Macarulla T.

Cancers (Basel). 2020 Mar 31;12(4). pii: E844. doi: 10.3390/cancers12040844. Review.

2.

Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy: A Systematic Literature Review.

Macarulla T, Hendifar AE, Li CP, Reni M, Riess H, Tempero MA, Dueck AC, Botteman MF, Deshpande CG, Lucas EJ, Oh DY.

Pancreas. 2020 Mar;49(3):393-407. doi: 10.1097/MPA.0000000000001507.

3.

Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial.

Javle M, Borbath I, Clarke S, Hitre E, Louvet C, Macarulla T, Oh D, Spratlin J, Valle J, Weiss K, Berman C, Howland M, Ye Y, Cho T, Moran S, Abou-Alfa G.

Ann Oncol. 2019 Jul;30 Suppl 4:iv62. doi: 10.1093/annonc/mdz155.224. Epub 2019 Dec 4. No abstract available.

PMID:
32085233
4.

Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial.

Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall M, Park J, Hochhauser D, Arnold D, Oh D, Reinacher-Schick A, Tortora G, Algül H, O'Reilly E, McGuinness D, Cui K, Schlienger K, Locker G, Kindler H.

Ann Oncol. 2019 Jul;30 Suppl 4:iv152. doi: 10.1093/annonc/mdz183. Epub 2019 Dec 4. No abstract available.

PMID:
32085054
5.

An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes.

Reni M, Riess H, O'Reilly E, Santoro A, Park J, Bekaii-Saab T, Tempero M, Shan Y, Macarulla T, Van Cutsem E, Noel M, Berlin J, Biankin A, Dhani N, Frassineti G, Goldstein D, Romano A, Bruchec YL, Philip P.

Ann Oncol. 2019 Jul;30 Suppl 4:iv126. doi: 10.1093/annonc/mdz154. Epub 2019 Dec 4. No abstract available.

PMID:
32085016
6.

Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study.

Tempero M, Oh D, Macarulla T, Reni M, Van Cutsem E, Hendifar A, Waldschmidt D, Starling N, Bachet J, Chang H, Maurel J, Lonardi S, Coussens L, Fong L, Tsao L, Cole G Jr, James D, Tabernero J.

Ann Oncol. 2019 Jul;30 Suppl 4:iv126. doi: 10.1093/annonc/mdz154.001. Epub 2019 Dec 4. No abstract available.

PMID:
32085015
7.

A phase 1/2, open-label, dose-expansion study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer.

Wainberg Z, Boland P, Lieu C, Dayyani F, Macarulla T, Zhang B, Belanger B, Moore Y, Wang T, Maxwell F, Dean A.

Ann Oncol. 2019 Jul;30 Suppl 4:iv123. doi: 10.1093/annonc/mdz157.004. Epub 2019 Dec 4. No abstract available.

PMID:
32085008
8.

Analysis of patient screening in the phase III, international, randomized, open-label APACT trial.

Reni M, Winter J, Tortora G, Pelzer U, Riess H, Chang H, O'Reilly E, Oh D, Diaz IA, Milella M, Bendell J, Garlipp B, Tempero M, Macarulla T, Van Cutsem E, Berlin J, Goldstein D, Lu B, Jeanes J, Philip P.

Ann Oncol. 2019 Jul;30 Suppl 4:iv110. doi: 10.1093/annonc/mdz156. Epub 2019 Dec 4. No abstract available.

PMID:
32084969
9.

Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial.

Golan T, Kindler HL, Park JO, Reni M, Macarulla T, Hammel P, Van Cutsem E, Arnold D, Hochhauser D, McGuinness D, Locker GY, Goranova T, Schatz P, Liu YZ, Hall MJ.

J Clin Oncol. 2020 Feb 19:JCO1901890. doi: 10.1200/JCO.19.01890. [Epub ahead of print]

PMID:
32073954
10.

First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study.

Taieb J, Prager GW, Melisi D, Westphalen CB, D'Esquermes N, Ferreras A, Carrato A, Macarulla T.

ESMO Open. 2020 Jan;5(1). pii: e000587. doi: 10.1136/esmoopen-2019-000587.

11.

The role of PIGF blockade in the treatment of colorectal cancer: overcoming the pitfalls.

Macarulla T, Montagut C, Sánchez-Martin FJ, Granja M, Verdaguer H, Sastre J, Tabernero J.

Expert Opin Biol Ther. 2020 Jan;20(1):15-22. doi: 10.1080/14712598.2020.1677603. Epub 2019 Oct 16.

PMID:
31608707
12.

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.

Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, Choo SP, Hollebecque A, Sung MW, Lim HY, Mazzaferro V, Trojan J, Zhu AX, Yoon JH, Sharma S, Lin ZZ, Chan SL, Faivre S, Feun LG, Yen CJ, Dufour JF, Palmer DH, Llovet JM, Manoogian M, Tugnait M, Stransky N, Hagel M, Kohl NE, Lengauer C, Sherwin CA, Schmidt-Kittler O, Hoeflich KP, Shi H, Wolf BB, Kang YK.

Cancer Discov. 2019 Dec;9(12):1696-1707. doi: 10.1158/2159-8290.CD-19-0555. Epub 2019 Oct 1.

13.

Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib.

Hammel P, Kindler HL, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Joo S, Yoo HK, Patel N, Golan T; POLO Investigators.

Ann Oncol. 2019 Dec 1;30(12):1959-1968. doi: 10.1093/annonc/mdz406.

14.

Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer.

Gueorguieva I, Tabernero J, Melisi D, Macarulla T, Merz V, Waterhouse TH, Miles C, Lahn MM, Cleverly A, Benhadji KA.

Cancer Chemother Pharmacol. 2019 Nov;84(5):1003-1015. doi: 10.1007/s00280-019-03931-1. Epub 2019 Sep 3.

PMID:
31482224
15.

Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer.

Chen LT, Macarulla T, Blanc JF, Mirakhur B, Jong FA, Belanger B, Bekaii-Saab T, Siveke JT.

Cancers (Basel). 2019 Jul 28;11(8). pii: E1068. doi: 10.3390/cancers11081068.

16.

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer.

Elez E, Chianese C, Sanz-García E, Martinelli E, Noguerido A, Mancuso FM, Caratù G, Matito J, Grasselli J, Cardone C, Esposito Abate R, Martini G, Santos C, Macarulla T, Argilés G, Capdevila J, Garcia A, Mulet N, Maiello E, Normanno N, Jones F, Tabernero J, Ciardello F, Salazar R, Vivancos A.

Mol Oncol. 2019 Sep;13(9):1827-1835. doi: 10.1002/1878-0261.12547. Epub 2019 Jul 31.

17.

Reply to I. Pecora et al.

Macarulla T, Hidalgo M.

J Clin Oncol. 2019 Aug 1;37(22):1979. doi: 10.1200/JCO.19.00697. Epub 2019 Jun 12. No abstract available.

PMID:
31188724
18.

Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence.

Seufferlein T, Hammel P, Delpero JR, Macarulla T, Pfeiffer P, Prager GW, Reni M, Falconi M, Philip PA, Van Cutsem E.

Cancer Treat Rev. 2019 Jul;77:1-10. doi: 10.1016/j.ctrv.2019.05.007. Epub 2019 May 29. Review.

PMID:
31163334
19.

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL.

N Engl J Med. 2019 Jul 25;381(4):317-327. doi: 10.1056/NEJMoa1903387. Epub 2019 Jun 2.

20.

RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma.

Qin S, Finn RS, Kudo M, Meyer T, Vogel A, Ducreux M, Macarulla TM, Tomasello G, Boisserie F, Hou J, Li X, Song J, Zhu AX.

Future Oncol. 2019 Jun;15(16):1811-1822. doi: 10.2217/fon-2019-0097. Epub 2019 Apr 10.

21.

TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer.

Melisi D, Garcia-Carbonero R, Macarulla T, Pezet D, Deplanque G, Fuchs M, Trojan J, Kozloff M, Simionato F, Cleverly A, Smith C, Wang S, Man M, Driscoll KE, Estrem ST, Lahn MMF, Benhadji KA, Tabernero J.

Cancer Chemother Pharmacol. 2019 May;83(5):975-991. doi: 10.1007/s00280-019-03807-4. Epub 2019 Mar 18.

PMID:
30887178
22.

Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial.

Macarulla T, Blanc JF, Wang-Gillam A, Chen LT, Siveke JT, Mirakhur B, Chen J, de Jong FA.

J Geriatr Oncol. 2019 May;10(3):427-435. doi: 10.1016/j.jgo.2019.02.011. Epub 2019 Mar 4.

23.

CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine.

Sonbol MB, Ahn DH, Goldstein D, Okusaka T, Tabernero J, Macarulla T, Reni M, Li CP, O'Neil B, Van Cutsem E, Bekaii-Saab T.

Future Oncol. 2019 Apr;15(12):1295-1302. doi: 10.2217/fon-2018-0903. Epub 2019 Feb 15.

PMID:
30768369
24.

Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2.

Macarulla T, Pazo-Cid R, Guillén-Ponce C, López R, Vera R, Reboredo M, Muñoz Martin A, Rivera F, Díaz Beveridge R, La Casta A, Martín Valadés J, Martínez-Galán J, Ales I, Sastre J, Perea S, Hidalgo M.

J Clin Oncol. 2019 Jan 20;37(3):230-238. doi: 10.1200/JCO.18.00089. Epub 2018 Dec 4.

PMID:
30523758
25.

New Horizons in the Treatment of Metastatic Pancreatic Cancer: A Review of the Key Biology Features and the Most Recent Advances to Treat Metastatic Pancreatic Cancer.

Verdaguer H, Arroyo A, Macarulla T.

Target Oncol. 2018 Dec;13(6):691-704. doi: 10.1007/s11523-018-0609-7. Review.

PMID:
30470972
26.

Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial.

Chen LT, Siveke JT, Wang-Gillam A, Li CP, Bodoky G, Dean AP, Shan YS, Jameson GS, Macarulla T, Lee KH, Cunningham D, Blanc JF, Chiu CF, Schwartsmann G, Braiteh FS, Mamlouk K, Belanger B, de Jong FA, Hubner RA.

Eur J Cancer. 2018 Dec;105:71-78. doi: 10.1016/j.ejca.2018.09.010. Epub 2018 Nov 8.

27.

First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors.

Elez E, Gomez-Roca C, Soto Matos-Pita A, Argiles G, Valentin T, Coronado C, Iglesias J, Macarulla T, Betrian S, Fudio S, Zaragoza K, Tabernero J, Delord JP.

Invest New Drugs. 2019 Aug;37(4):674-683. doi: 10.1007/s10637-018-0674-x. Epub 2018 Nov 9.

PMID:
30411218
28.

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer.

Melisi D, Garcia-Carbonero R, Macarulla T, Pezet D, Deplanque G, Fuchs M, Trojan J, Oettle H, Kozloff M, Cleverly A, Smith C, Estrem ST, Gueorguieva I, Lahn MMF, Blunt A, Benhadji KA, Tabernero J.

Br J Cancer. 2018 Nov;119(10):1208-1214. doi: 10.1038/s41416-018-0246-z. Epub 2018 Oct 15.

29.

Management and supportive treatment of frail patients with metastatic pancreatic cancer.

Macarulla T, Carrato A, Díaz R, García A, Laquente B, Sastre J, Álvarez R, Muñoz A, Hidalgo M.

J Geriatr Oncol. 2019 May;10(3):398-404. doi: 10.1016/j.jgo.2018.06.005. Epub 2018 Jul 11. Review.

PMID:
30005980
30.

From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer.

Martín AM, Hidalgo M, Alvarez R, Arrazubi V, Martínez-Galán J, Salgado M, Macarulla T, Carrato A.

J Cancer. 2018 Apr 30;9(11):1978-1988. doi: 10.7150/jca.23716. eCollection 2018. Review.

31.

Efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma in a phase 3, randomized, open-label, multicenter study - Trial in progress.

Qin S, Finn R, Kudo M, Meyer T, Vogel A, Ducreux M, Macarulla T, Tomasello G, Boisserie F, Hou J, Li C, Song J, Zhu A.

Ann Oncol. 2018 Jun;29 Suppl 5:v51. doi: 10.1093/annonc/mdy151.181. Epub 2020 Jan 7. No abstract available.

32.

Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice.

Velasco AG, Macarulla T, Sánchez CB, Martín M, García C, Pericay C, Merino S, Visa L, Martín T, Pedraza M, Carnero B, Guardeño R, Pellín L, Vilanova D, Laquente B.

Ann Oncol. 2018 Jun;29 Suppl 5:v45. doi: 10.1093/annonc/mdy151.159. Epub 2020 Jan 7. No abstract available.

33.

Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer.

Van Cutsem E, Hidalgo M, Canon JL, Macarulla T, Bazin I, Poddubskaya E, Manojlovic N, Radenkovic D, Verslype C, Raymond E, Cubillo A, Schueler A, Zhao C, Hammel P.

Int J Cancer. 2018 Oct 15;143(8):2053-2064. doi: 10.1002/ijc.31603. Epub 2018 Aug 9.

34.

Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease.

Ter Veer E, van Rijssen LB, Besselink MG, Mali RMA, Berlin JD, Boeck S, Bonnetain F, Chau I, Conroy T, Van Cutsem E, Deplanque G, Friess H, Glimelius B, Goldstein D, Herrmann R, Labianca R, Van Laethem JL, Macarulla T, van der Meer JHM, Neoptolemos JP, Okusaka T, O'Reilly EM, Pelzer U, Philip PA, van der Poel MJ, Reni M, Scheithauer W, Siveke JT, Verslype C, Busch OR, Wilmink JW, van Oijen MGH, van Laarhoven HWM.

Lancet Oncol. 2018 Mar;19(3):e151-e160. doi: 10.1016/S1470-2045(18)30098-6.

35.

Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies.

Hurwitz H, Van Cutsem E, Bendell J, Hidalgo M, Li CP, Salvo MG, Macarulla T, Sahai V, Sama A, Greeno E, Yu KH, Verslype C, Dawkins F, Walker C, Clark J, O'Reilly EM.

Invest New Drugs. 2018 Aug;36(4):683-695. doi: 10.1007/s10637-018-0580-2. Epub 2018 Mar 6.

36.

Management of hyperbilirubinaemia in pancreatic cancer patients.

Álvarez R, Carrato A, Adeva J, Alés I, Prados S, Valladares M, Macarulla T, Muñoz A, Hidalgo M.

Eur J Cancer. 2018 May;94:26-36. doi: 10.1016/j.ejca.2018.01.078. Epub 2018 Mar 20. Review.

PMID:
29505968
37.

Corrigendum: mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer.

Zabala-Letona A, Arruabarrena-Aristorena A, Martín-Martín N, Fernandez-Ruiz S, Sutherland JD, Clasquin M, Tomas-Cortazar J, Jimenez J, Torres I, Quang P, Ximenez-Embun P, Bago R, Ugalde-Olano A, Loizaga-Iriarte A, Lacasa-Viscasillas I, Unda M, Torrano V, Cabrera D, van Liempd SM, Cendon Y, Castro E, Murray S, Revandkar A, Alimonti A, Zhang Y, Barnett A, Lein G, Pirman D, Cortazar AR, Arreal L, Prudkin L, Astobiza I, Valcarcel-Jimenez L, Zuñiga-García P, Fernandez-Dominguez I, Piva M, Caro-Maldonado A, Sánchez-Mosquera P, Castillo-Martín M, Serra V, Beraza N, Gentilella A, Thomas G, Azkargorta M, Elortza F, Farràs R, Olmos D, Efeyan A, Anguita J, Muñoz J, Falcón-Pérez JM, Barrio R, Macarulla T, Mato JM, Martinez-Chantar ML, Cordon-Cardo C, Aransay AM, Marks K, Baselga J, Tabernero J, Nuciforo P, Manning BD, Marjon K, Carracedo A.

Nature. 2018 Feb 22;554(7693):554. doi: 10.1038/nature25470. Epub 2018 Jan 17.

PMID:
29342137
38.

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.

Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T.

J Clin Oncol. 2018 Jan 20;36(3):276-282. doi: 10.1200/JCO.2017.75.5009. Epub 2017 Nov 28.

39.

Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial.

Ruff P, Van Cutsem E, Lakomy R, Prausova J, van Hazel GA, Moiseyenko VM, Soussan-Lazard K, Dochy E, Magherini E, Macarulla T, Papamichael D.

J Geriatr Oncol. 2018 Jan;9(1):32-39. doi: 10.1016/j.jgo.2017.07.010. Epub 2017 Aug 12.

PMID:
28807738
40.

Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment.

Verdaguer H, Saurí T, Macarulla T.

J Gastrointest Oncol. 2017 Jun;8(3):405-417. doi: 10.21037/jgo.2016.11.15. Review.

41.

Overexpression of Yes Associated Protein 1, an Independent Prognostic Marker in Patients With Pancreatic Ductal Adenocarcinoma, Correlated With Liver Metastasis and Poor Prognosis.

Salcedo Allende MT, Zeron-Medina J, Hernandez J, Macarulla T, Balsells J, Merino X, Allende H, Tabernero J, Ramon Y Cajal S.

Pancreas. 2017 Aug;46(7):913-920. doi: 10.1097/MPA.0000000000000867.

PMID:
28697132
42.

mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer.

Zabala-Letona A, Arruabarrena-Aristorena A, Martín-Martín N, Fernandez-Ruiz S, Sutherland JD, Clasquin M, Tomas-Cortazar J, Jimenez J, Torres I, Quang P, Ximenez-Embun P, Bago R, Ugalde-Olano A, Loizaga-Iriarte A, Lacasa-Viscasillas I, Unda M, Torrano V, Cabrera D, van Liempd SM, Cendon Y, Castro E, Murray S, Revandkar A, Alimonti A, Zhang Y, Barnett A, Lein G, Pirman D, Cortazar AR, Arreal L, Prudkin L, Astobiza I, Valcarcel-Jimenez L, Zuñiga-García P, Fernandez-Dominguez I, Piva M, Caro-Maldonado A, Sánchez-Mosquera P, Castillo-Martín M, Serra V, Beraza N, Gentilella A, Thomas G, Azkargorta M, Elortza F, Farràs R, Olmos D, Efeyan A, Anguita J, Muñoz J, Falcón-Pérez JM, Barrio R, Macarulla T, Mato JM, Martinez-Chantar ML, Cordon-Cardo C, Aransay AM, Marks K, Baselga J, Tabernero J, Nuciforo P, Manning BD, Marjon K, Carracedo A.

Nature. 2017 Jul 6;547(7661):109-113. doi: 10.1038/nature22964. Epub 2017 Jun 28. Erratum in: Nature. 2018 Jan 17;:.

43.

Adjuvant treatment for pancreatic ductal carcinoma.

Macarulla T, Fernández T, Gallardo ME, Hernando O, López AM, Hidalgo M.

Clin Transl Oncol. 2017 Oct;19(10):1199-1204. doi: 10.1007/s12094-017-1683-5. Epub 2017 Jun 21. Review.

PMID:
28639051
44.

Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights.

Dienstmann R, Elez E, Argiles G, Matos I, Sanz-Garcia E, Ortiz C, Macarulla T, Capdevila J, Alsina M, Sauri T, Verdaguer H, Vilaro M, Ruiz-Pace F, Viaplana C, Garcia A, Landolfi S, Palmer HG, Nuciforo P, Rodon J, Vivancos A, Tabernero J.

Mol Oncol. 2017 Sep;11(9):1263-1272. doi: 10.1002/1878-0261.12099. Epub 2017 Jul 20.

45.

Pancreatic cancer heterogeneity and response to Mek inhibition.

Pedersen K, Bilal F, Bernadó Morales C, Salcedo MT, Macarulla T, Massó-Vallés D, Mohan V, Vivancos A, Carreras MJ, Serres X, Abu-Suboh M, Balsells J, Allende E, Sagi I, Soucek L, Tabernero J, Arribas J.

Oncogene. 2017 Oct 5;36(40):5639-5647. doi: 10.1038/onc.2017.174. Epub 2017 Jun 5.

PMID:
28581516
46.

Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI±5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy.

Blanc JF, Hubner R, Li CP, Wang-Gillam A, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Chiu CF, Schwartsmann G, Braiteh F, Von Hoff D, Chen LT, Mamlouk K, Bhargava P, de Jong F, Siveke J.

Ann Oncol. 2017 Jun;28 Suppl 3:iii7. doi: 10.1093/annonc/mdx263.017. No abstract available.

47.

CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy.

Chen LT, Wang-Gillam A, Shan YS, Macarulla T, Blanc JF, Hubner R, Chiu CF, Schwartsmann G, Siveke J, Marc PJ, Belanger B, de Jong F, Mamlouk K, Von Hoff D.

Ann Oncol. 2017 Jun;28 Suppl 3:iii6-iii7. doi: 10.1093/annonc/mdx263.016. No abstract available.

48.

Impact in prognosis of circulating tumor DNA mutant allele fraction (MAF) in RAS mutant metastatic colorectal cancer (mCRC).

Enrique SG, Elez E, Caratu G, Matito J, Garcia A, Grasselli J, Martínez-Villacampa M, Santos C, Mulet N, Vidal J, Argiles G, Macarulla T, Capdevila J, Sauri T, Matos I, Aranda E, Jones F, Dientsmann R, Montagut C, Tabernero J, Salazar R, Vivancos A.

Ann Oncol. 2017 Jun;28 Suppl 3:iii140. doi: 10.1093/annonc/mdx262.009. No abstract available.

49.

Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer.

Grasselli J, Elez E, Caratù G, Matito J, Santos C, Macarulla T, Vidal J, Garcia M, Viéitez JM, Paéz D, Falcó E, Lopez Lopez C, Aranda E, Jones F, Sikri V, Nuciforo P, Fasani R, Tabernero J, Montagut C, Azuara D, Dienstmann R, Salazar R, Vivancos A.

Ann Oncol. 2017 Jun 1;28(6):1294-1301. doi: 10.1093/annonc/mdx112.

50.

Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain.

Hidalgo M, Álvarez R, Gallego J, Guillén-Ponce C, Laquente B, Macarulla T, Muñoz A, Salgado M, Vera R, Adeva J, Alés I, Arévalo S, Blázquez J, Calsina A, Carmona A, de Madaria E, Díaz R, Díez L, Fernández T, de Paredes BG, Gallardo ME, González I, Hernando O, Jiménez P, López A, López C, López-Ríos F, Martín E, Martínez J, Martínez A, Montans J, Pazo R, Plaza JC, Peiró I, Reina JJ, Sanjuanbenito A, Yaya R, Carrato A.

Clin Transl Oncol. 2017 Jun;19(6):667-681. doi: 10.1007/s12094-016-1594-x. Epub 2016 Dec 19.

Supplemental Content

Loading ...
Support Center